Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Hiromi RakugiKotaro Sugimoto

Abstract

The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I-III hypertension, hypertension with moderate renal dysfunction, hypertension with type 2 diabetes mellitus with albuminuria, and hypertension associated with primary aldosteronism. Hyperkalemia has long been recognized as a potential side effect occurring during treatment with MR blockers, but there is a lack of understanding and guidance about the appropriate management of hyperkalemia during antihypertensive therapy with MR blockers, especially in regard to the newer agent esaxerenone. In this article, we first highlight risk factors for hyperkalemia, including advanced chronic kidney disease, diabetes mellitus, cardiovascular disease, age, and use of renin-angiotensin-aldosterone system inhibitors. Next, we examine approaches to prevention and management, including potassium monitoring, diet, and the use of appropriate therapeutic techniques. Finally, we summarize the currently available data for esaxerenone and hyperkalemia. Proper management of serum potassium is required to ensure safe clinical use of MR blockers, including awareness of at...Continue Reading

References

Jan 1, 1991·European Neurology·S ShintaniH Tsukagoshi
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Feb 1, 1993·British Journal of Anaesthesia·S J Freeman, A D Fale
Aug 6, 2002·American Journal of Hypertension·Myron H WeinbergerRobert J Weiss
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
May 21, 2003·Circulation·Nancy J Brown
Oct 24, 2003·American Journal of Hypertension·Mari Konishi NishizakaDavid A Calhoun
Jan 23, 2004·Journal of the American College of Cardiology·John E Macdonald, Allan D Struthers
Mar 18, 2004·Annals of Clinical Biochemistry·Kenji HiraTsuguya Fukui
Apr 15, 2004·The American Journal of Cardiology·Gordon H WilliamsScott L Krause
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·D G LevyJ W Funder
Aug 6, 2004·The New England Journal of Medicine·David N JuurlinkDonald A Redelmeier
Feb 5, 2005·American Journal of Hypertension·Atsuhisa SatoTakao Saruta
Apr 23, 2005·BMJ : British Medical Journal·Abbas IsmailGillian Burrows
Jun 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Stefano BianchiVito M Campese
Dec 1, 2005·Kidney International·Katrine Jordan SchjoedtHans-Henrik Parving
Jun 27, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Martin MacKinnonHeather D Clark
Oct 21, 2006·Journal of Hypertension·Anton H van den MeirackerFrans Boomsma
Feb 21, 2007·Hypertension·Neil ChapmanUNKNOWN Anglo-Scandinavian Cardiac Outcomes Trial Investigators
Feb 1, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Brian T MontagueGregory K Buller
Apr 22, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Leszek TylickiBolesław Rutkowski
Jul 25, 2008·The New England Journal of Medicine·Nikolaus BüchnerBernhard K Krämer
Sep 30, 2009·Archives of Internal Medicine·Joy M WeinbergUNKNOWN African American Study of Hypertension and Kidney Disease Collaborative Research Group
Jan 21, 2010·Journal of General Internal Medicine·Marsha A RaebelDavid H Smith
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Dec 7, 2010·Journal of the American Society of Hypertension : JASH·Jodi HeshkaBrendan B McCormick
Sep 8, 2011·The Journal of Clinical Hypertension·Murray Epstein, David A Calhoun
Sep 29, 2011·British Journal of Clinical Pharmacology·Nicola C EdwardsJonathan N Townend
Jan 12, 2012·JAMA : the Journal of the American Medical Association·Abhinav GoyalMikhail Kosiborod
Jan 31, 2012·Journal of the American Geriatrics Society·Paul E DrawzMahboob Rahman
Feb 22, 2012·The American Journal of Cardiology·Nishank JainSubhash Banerjee
Mar 21, 2012·Hypertension·Michael H AldermanUNKNOWN Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.